Cargando…

Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model

PURPOSE: Success in treating nephroblastoma in high-income countries has been transferred to some resource-constrained settings; multicenter studies report disease-free survival of greater than 70%. However, few reports present care models with rural-based components, care tasks shifted to internist...

Descripción completa

Detalles Bibliográficos
Autores principales: Shyirambere, Cyprien, Xu, Mary Jue, Elmore, Shekinah Nefreteri, Fadelu, Temidayo, May, Leana, Tapela, Neo, Umuhizi, Denis Gilbert, Uwizeye, Frank Regis, Driscoll, Caitlin, Muhayimana, Clemence, Hategekimana, Vedaste, Rubagumya, Fidel, Nzayisenga, Ignace, Shulman, Lawrence N., Mpunga, Tharcisse, Lehmann, Leslie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495448/
https://www.ncbi.nlm.nih.gov/pubmed/28717689
http://dx.doi.org/10.1200/JGO.2015.000067
_version_ 1783247808692748288
author Shyirambere, Cyprien
Xu, Mary Jue
Elmore, Shekinah Nefreteri
Fadelu, Temidayo
May, Leana
Tapela, Neo
Umuhizi, Denis Gilbert
Uwizeye, Frank Regis
Driscoll, Caitlin
Muhayimana, Clemence
Hategekimana, Vedaste
Rubagumya, Fidel
Nzayisenga, Ignace
Shulman, Lawrence N.
Mpunga, Tharcisse
Lehmann, Leslie E.
author_facet Shyirambere, Cyprien
Xu, Mary Jue
Elmore, Shekinah Nefreteri
Fadelu, Temidayo
May, Leana
Tapela, Neo
Umuhizi, Denis Gilbert
Uwizeye, Frank Regis
Driscoll, Caitlin
Muhayimana, Clemence
Hategekimana, Vedaste
Rubagumya, Fidel
Nzayisenga, Ignace
Shulman, Lawrence N.
Mpunga, Tharcisse
Lehmann, Leslie E.
author_sort Shyirambere, Cyprien
collection PubMed
description PURPOSE: Success in treating nephroblastoma in high-income countries has been transferred to some resource-constrained settings; multicenter studies report disease-free survival of greater than 70%. However, few reports present care models with rural-based components, care tasks shifted to internists and pediatricians, and data collection structured for monitoring and evaluation. Here, we report clinical outcomes and protocol compliance for patients with nephroblastoma evaluated at Butaro Cancer Center of Excellence in Rwanda. PATIENTS AND METHODS: This retrospective study reports the care of 53 patients evaluated between July 1, 2012, and June 30, 2014. Patients receiving less than half of their chemotherapy at Butaro Cancer Center of Excellence were excluded. RESULTS: Of the 53 patients included, 9.4% had stage I, 13.2% had stage II, 24.5% had stage III, 26.4% had stage IV, and 5.7% had stage V disease; the remaining 20.8% had unknown stage disease from inadequate work-up or unavailable surgical report. The incidence of neutropenia increased with treatment progression, and the greatest proportion of delays occurred during the surgical referral phase. At the end of the study period, 32.1% of patients (n = 17) remained alive after treatment; 24.5% (n = 13) remained alive while continuing treatment, including one patient with recurrent disease; 30.2% (n = 16) died; and 13.2% (n = 7) were lost to follow-up. CONCLUSION: Our findings confirm that nephroblastoma can be effectively treated in resource-constrained settings. Using an approach in which chemotherapy is delivered at a rural-based center by nononcologists and data are used for routine evaluation, care can be delivered in safe, novel ways. Protocol modifications to mitigate chemotherapy toxicities and strong communication between the multidisciplinary team members will likely minimize delays and further improve outcomes in similar settings.
format Online
Article
Text
id pubmed-5495448
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-54954482017-07-17 Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model Shyirambere, Cyprien Xu, Mary Jue Elmore, Shekinah Nefreteri Fadelu, Temidayo May, Leana Tapela, Neo Umuhizi, Denis Gilbert Uwizeye, Frank Regis Driscoll, Caitlin Muhayimana, Clemence Hategekimana, Vedaste Rubagumya, Fidel Nzayisenga, Ignace Shulman, Lawrence N. Mpunga, Tharcisse Lehmann, Leslie E. J Glob Oncol Original Reports PURPOSE: Success in treating nephroblastoma in high-income countries has been transferred to some resource-constrained settings; multicenter studies report disease-free survival of greater than 70%. However, few reports present care models with rural-based components, care tasks shifted to internists and pediatricians, and data collection structured for monitoring and evaluation. Here, we report clinical outcomes and protocol compliance for patients with nephroblastoma evaluated at Butaro Cancer Center of Excellence in Rwanda. PATIENTS AND METHODS: This retrospective study reports the care of 53 patients evaluated between July 1, 2012, and June 30, 2014. Patients receiving less than half of their chemotherapy at Butaro Cancer Center of Excellence were excluded. RESULTS: Of the 53 patients included, 9.4% had stage I, 13.2% had stage II, 24.5% had stage III, 26.4% had stage IV, and 5.7% had stage V disease; the remaining 20.8% had unknown stage disease from inadequate work-up or unavailable surgical report. The incidence of neutropenia increased with treatment progression, and the greatest proportion of delays occurred during the surgical referral phase. At the end of the study period, 32.1% of patients (n = 17) remained alive after treatment; 24.5% (n = 13) remained alive while continuing treatment, including one patient with recurrent disease; 30.2% (n = 16) died; and 13.2% (n = 7) were lost to follow-up. CONCLUSION: Our findings confirm that nephroblastoma can be effectively treated in resource-constrained settings. Using an approach in which chemotherapy is delivered at a rural-based center by nononcologists and data are used for routine evaluation, care can be delivered in safe, novel ways. Protocol modifications to mitigate chemotherapy toxicities and strong communication between the multidisciplinary team members will likely minimize delays and further improve outcomes in similar settings. American Society of Clinical Oncology 2016-01-27 /pmc/articles/PMC5495448/ /pubmed/28717689 http://dx.doi.org/10.1200/JGO.2015.000067 Text en © 2016 by American Society of Clinical Oncology http://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Reports
Shyirambere, Cyprien
Xu, Mary Jue
Elmore, Shekinah Nefreteri
Fadelu, Temidayo
May, Leana
Tapela, Neo
Umuhizi, Denis Gilbert
Uwizeye, Frank Regis
Driscoll, Caitlin
Muhayimana, Clemence
Hategekimana, Vedaste
Rubagumya, Fidel
Nzayisenga, Ignace
Shulman, Lawrence N.
Mpunga, Tharcisse
Lehmann, Leslie E.
Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model
title Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model
title_full Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model
title_fullStr Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model
title_full_unstemmed Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model
title_short Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model
title_sort treating nephroblastoma in rwanda: using international society of pediatric oncology guidelines in a novel oncologic care model
topic Original Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495448/
https://www.ncbi.nlm.nih.gov/pubmed/28717689
http://dx.doi.org/10.1200/JGO.2015.000067
work_keys_str_mv AT shyiramberecyprien treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel
AT xumaryjue treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel
AT elmoreshekinahnefreteri treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel
AT fadelutemidayo treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel
AT mayleana treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel
AT tapelaneo treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel
AT umuhizidenisgilbert treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel
AT uwizeyefrankregis treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel
AT driscollcaitlin treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel
AT muhayimanaclemence treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel
AT hategekimanavedaste treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel
AT rubagumyafidel treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel
AT nzayisengaignace treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel
AT shulmanlawrencen treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel
AT mpungatharcisse treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel
AT lehmannlesliee treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel